
Frequently Asked Questions
Nu-V3 is the only patented, miniaturized and wearable 24/7, non-invasive and non-pharmaceutical neuromodulation device designed to mitigate or eliminate the debilitating symptoms of acute and chronic pain, anxiety, depression and sleeplessness. We taken great care to be sure Nu-V3 is easily accessible, simple to apply and use, while allowing the patient to perform almost any everyday activity.
Nu-V3 works by sending a tiny micro-signal through the auricular (ear) area, to the cranial nerves, more specifically the vagus, facial, trigeminal and glossopharyngeal nerves, helping to stimulate enkephalins (a strong endorphin) and over a period of weeks, re-establish balance of the autonomic nervous system.
Vagal nerve stimulation, vasodilation (increased blood flow) and vital enkephalin production are the three main elements of the non-invasive neuromodulation Nu-V3 delivers.
Nu-V3 has been developed to manage and mitigate the symptoms of pain, anxiety, depression and sleeplessness. Other benefits of Nu-V3 are an increase in activity, lesser dependence on as-needed pain, anxiety and depression medications and an overall increase in quality of life.
Further research will lead to extended uses for Nu-V3 such as neurodegenerative diseases (Parkinson's, Alzheimers, Als), cardiovascular disease such as AFib, post-op surgery recovery, and addiction or reliance upon pain medication.
Nu-V3Pro has also been developed to enhance performance in elite athletes and active military.
Nu-V3 is worn comfortably on the ear and allows the patient to sleep, shower and perform almost any everyday activity while wearing Nu-V3. Nu-V3 5.0 may even be worn during sports such as golf or tennis.
Nu-V3 is worn for 12 weeks throughout the treatment program. Follow-up treatments are available if needed, but Nu-V3 is designed to be discontinued once the patient's ANS is in balance and progresses from dysfunctional to functional.
Because Nu-V3 delivers the science of neuromodulation non-invasiveley, non-pharmaceutically and with such a tiny micro-signal, it is considered very safe. There are no known negative side effects from Nu-V3 or the Nu-V3 Treatment Program.
Nu-V3 has also been designated as 'non significant risk' (NSR) by the institutional review board (IRB) responsible for approving our clinical programs.
Yes, Nu-V3 has been shown to be safe and effective by clinical trial and numerous case studies. Our clinical programs will continue for the purpose of creating awareness and demand, while also validating Nu-V3 for numerous expanded uses.
Nu-V3 utilizes the well established science of Neuromodulation. While Nu-Life did not invent or discover the science of neuromodulation, we developed a minaturized, non-invasive, easy to use technology that delivers this science 24/7 in a way that no one else does.
Neuromodulation is technology that acts directly upon nerves. It is the alteration - or modulation - of nerve activity by delivering either electrical or pharmaceutical (drug) agents directly to a target area.
​
Nu-Life's Nu-V3 technology delivers a micro-electrical signal to create the cranial nerve modulation non-invasively and non-pharmaceutically directly through the auricular (ear) area, all while allowing the patient to perform almost any everyday activity.
While there are a number of forms of neuromodulation, what sets Nu-V3 apart is the ability to deliver the stimulation non-invasively, non-pharmaceutically. Nu-V3 is also comfortable to wear on the ear and simple to use, significantly increasing patient compliance. Because Nu-V3 is miniaturized and lightweight it enables the patient to perform almost any everyday activity. The most important distinction is the long term benefit Nu-V3 offers and the opportunity to discontinue treatment once the patient's autonomic nervous system (ANS) has become functional once again.
We do anticipate the cost of the Nu-V3 program to be covered in a number of ways, from self-insured corporations for their employees to major healthcare providers and agencies.
In today's ever-changing environment of insurance coverage for healthcare, the significantly lower cost of treatment, ease of use and low risk (no negative side effetcs) allows Nu-V3 to be considered as standard of care as we acquire regulatory clearances. Even private pay becomes an advantage over the cost of the patient's existing out-of-pocket cost.
Anyone suffering severely from the symptoms of pain, anxiety, depression and or sleeplessness. Our initial patient populations include those suffering from neuropathy, back and joint pain, PTSD, arthritis and rheumatoid arthritis. However, literally anyone suffering from these symptoms may find Nu-V3 is a real answer for them.

